首页> 美国卫生研究院文献>Antimicrobial Agents and Chemotherapy >Note: Bioavailability of Aciclovir after Oral Administration of Aciclovir and Its Prodrug Valaciclovir to Patients with Leukopenia after Chemotherapy
【2h】

Note: Bioavailability of Aciclovir after Oral Administration of Aciclovir and Its Prodrug Valaciclovir to Patients with Leukopenia after Chemotherapy

机译:注意:口服阿昔洛韦及其前药伐昔洛韦对化疗后白细胞减少症患者的生物利用度

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The median bioavailabilities of aciclovir after administration of aciclovir and its prodrug valaciclovir were 21.5 and 70.1%, respectively, in 12 patients with malignant hematological diseases with leukopenia after chemotherapy. The interindividual variations of the bioavailability were 48.5 and 21.0% after administration of aciclovir and valaciclovir, respectively. Neither the bioavailability nor the interindividual variation of area under the concentration-time curve of oral aciclovir or valaciclovir differed from that reported in healthy volunteers.
机译:在12例恶性血液病伴化疗后白细胞减少的患者中,服用阿昔洛韦及其前药valaciclovir后,阿昔洛韦的中位生物利用度分别为21.5%和70.1%。服用阿昔洛韦和伐昔洛韦后,生物利用度的个体差异分别为48.5%和21.0%。口服阿昔洛韦或伐昔洛韦的浓度-时间曲线下的生物利用度或面积之间的个体差异均与健康志愿者的报道相同。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号